Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study

Maria Giuseppa Vitale, Stefania Pipitone, Marta Venturelli, Cinzia Baldessari, Camillo Porta, Federica Iannuzzi, Umberto Basso, Sarah Scagliarini, Paolo Andrea Zucali, Luca Galli, Sabrina Rossetti, Claudia Caserta, Sergio Bracarda, Roberto Iacovelli, Cristina Masini, Alessio Cortellini, Stefania Di Girolamo, Sebastiano Buti, Giuseppe Fornarini, Francesco CarrozzaMatteo Santoni, Francesco Caputo, Stefania Giaquinta, Sara Balduzzi, Roberto D'Amico, Giovanna Vitale, Pasquale Mighali, Roberto Sabbatini

Research output: Contribution to journalArticle

Abstract

Background: Immunotherapy has brought clinical benefits to patients with metastatic renal cell cancer (mRCC). Most patients tolerate immunotherapy but serious immune-related adverse events (irAEs) have been reported. Some studies indicate a correlation between irAEs and clinical response in other cancer types (eg, lung cancer and melanoma). For patients with mRCC, the impact of irAE on clinical outcome is unknown. Patients and Methods: A retrospective review of 167 patients with mRCC treated with nivolumab as standard of care between March 2017 and January 2018 in 16 Italian centers was performed. irAEs were assessed using Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. Results: Any grade and grade 3/4 irAEs occurred in 46% and 8.9% of patients, respectively. The median time to appearance of irAEs was 10 weeks; 38.8% of patients required steroid treatment. The most common irAEs were cutaneous (33.7%) and gastrointestinal (23.3%). The median overall survival and progression-free survival were 20.13 and 7.86 months, respectively. Patients with irAEs showed a greater overall survival (hazard ratio, 0.38; 95% confidence interval [CI], 0.23-0.63) and progression-free survival (hazard ratio, 0.44; 95% CI, 0.29-0.66) benefit as well as better overall response rate (27.3% vs. 13.7%; odds ratio, 2.36; 95% CI, 1.03-5.44) and disease control rate (68.8% vs. 48%; odds ratio, 2.4; 95% CI, 1.23-4.67) if compared with those without irAEs. No correlation was found between steroid use and clinical outcomes. Conclusions: Our analysis revealed that the appearance of irAEs was associated with better outcomes in patients treated with nivolumab. This data may be limited by sample size and the retrospective nature of the study.

Original languageEnglish
JournalClinical Genitourinary Cancer
DOIs
Publication statusAccepted/In press - 2020

Keywords

  • Immunotherapy
  • IRAE
  • Metastatic renal cell carcinoma
  • Nivolumab
  • Outcome

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study'. Together they form a unique fingerprint.

  • Cite this

    Vitale, M. G., Pipitone, S., Venturelli, M., Baldessari, C., Porta, C., Iannuzzi, F., Basso, U., Scagliarini, S., Zucali, P. A., Galli, L., Rossetti, S., Caserta, C., Bracarda, S., Iacovelli, R., Masini, C., Cortellini, A., Di Girolamo, S., Buti, S., Fornarini, G., ... Sabbatini, R. (Accepted/In press). Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2020.05.010